AB 577 restricts health insurers and pharmacy benefit managers from steering patients away from in‑network clinicians for injected or infused medications and from forcing mail‑order or retail pathways when a treating in‑network provider determines clinic or office administration is medically necessary. It also bars insurers/PBMs from imposing higher cost sharing for provider‑administered drugs, from refusing payment to participating providers who administer covered drugs, and from contract terms that penalize physicians for dispensing oral medications.
The bill adds a provider obligation to secure the insured’s consent and provide a good‑faith estimate of applicable patient cost sharing before administering or sending a patient for an injected or infused medication when the actual site or administrator differs from the insurer’s direction. It defines key terms, excludes hospital outpatient facilities, and repeats a robust definition of pharmacy benefit manager — but it does not create an explicit enforcement mechanism or remedies in the text.
At a Glance
What It Does
AB 577 forbids insurers and PBMs from requiring self‑administration, forcing use of a particular in‑network infusion site, or mandating mail‑order supply for injected/infused drugs when an in‑network provider deems clinic/office administration medically necessary. It also prohibits cost‑sharing that disadvantages provider‑administered drugs and bars discriminatory contract clauses against physicians who dispense oral meds.
Who It Affects
In‑network physicians, infusion centers, clinics, community pharmacies, insurers and pharmacy benefit managers operating in California, and patients receiving injected, infused, or prescriber‑dispensed oral medications. The text implicates contract negotiators, benefits teams, and clinic billing staff.
Why It Matters
The bill shifts control of site‑of‑care and dispensing decisions toward the treating clinician’s medical judgment and toward patient choice, which could limit PBM and plan cost‑containment tools such as mandatory mail‑order, preferred infusion networks, and steering clauses in provider contracts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The core of AB 577 is straightforward: when a patient’s in‑network clinician determines a drug should be given by a clinician in an office, clinic, or infusion center, the insurer or PBM cannot require the patient to self‑administer, use a specific external infusion site selected by the plan, or be forced to receive the drug only via mail order for later administration. That shifts authority over how and where a drug is administered to the treating provider’s clinical judgment rather than the plan’s routing rules.
The bill extends the protection to dispensing of oral medications: insurers cannot require retail dispensing if the in‑network prescriber deems it clinically appropriate for a different in‑network pharmacy or for the prescriber to dispense under Section 4170 of the Business and Professions Code. It forbids plans or PBMs from paying physicians less than their contracted rate for a drug because it was dispensed by a physician, and it bars contract provisions that are designed to deter or punish physicians who dispense medications.When an insured ends up receiving a drug at a different location or from a different provider than the plan directed, AB 577 imposes an affirmative duty on the supplying or administering provider to obtain the insured’s consent and give a good‑faith estimate of the patient’s cost‑sharing amount before administration or sending the patient for treatment.
The bill supplies definitions — including a detailed description of a pharmacy benefit manager — and explicitly excludes hospital outpatient departments from the statutory definition of “physician’s office, clinic, or infusion center.”What the bill does not do is set out enforcement mechanics, civil penalties, or a private right of action; nor does it address how ERISA‑governed self‑funded plans are affected. The statutory language also contains duplicated and overlapping definitions and some drafting roughness (for example, duplicated PBM definitions and fractured phrasing around “medically necessary”), which will matter when agencies and courts interpret its reach.
The Five Things You Need to Know
Applies to health insurance policies issued, amended, or renewed on or after January 1, 2026 — the bill’s protections are tied to policy issuance/renewal rather than retroactive claims.
Prohibits requiring a patient to self‑administer or to use a specific in‑network provider, external infusion center, or home infusion pharmacy when the patient’s in‑network clinician determines clinician‑administered infusion is medically necessary.
Bans insurers/PBMs from mandating mail‑order supply for injected/infused medications and from imposing higher cost‑sharing for provider‑administered drugs than would apply if the drug were supplied by mail order.
Forbids plans/PBMs from refusing to authorize or pay participating in‑network providers for administering covered infused or injected drugs, and from reimbursing physicians at a lesser amount than their contracted rate because the physician dispensed the drug.
Requires the administering or supplying provider to obtain the insured’s consent and deliver a good‑faith estimate of the insured’s applicable cost‑sharing before administration when the actual administrator or site differs from the plan/PBM direction; hospital outpatient facilities are excluded from the definition of physician’s office, clinic, or infusion center.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Limits on steering for infused/injected medications
These clauses bar an insurer or PBM from forcing self‑administration, designating a single in‑network infusion site, or requiring mail‑order supply for injected/infused drugs when an in‑network provider says clinician administration in an office, clinic, or infusion center is medically necessary. Operationally, plans must accept the treating provider’s clinical determination and cannot condition coverage on following the plan’s preferred site or supply channel in those situations.
Cost‑sharing parity and payment obligations
The statute prohibits charging an insured greater copays, coinsurance, or other cost‑sharing for a covered injected/infused drug when it is furnished by an in‑network provider than would apply if the drug were supplied by mail order. It also requires plans to authorize and pay participating in‑network providers for administering covered infused or injected drugs when the medication otherwise would be covered, removing a leverage point plans sometimes use to steer care.
Protections for prescriber dispensing and non‑discrimination
These paragraphs prevent insurers and PBMs from forcing retail dispensing when the prescriber determines another in‑network pharmacy or the prescriber should dispense under Business & Professions Code Section 4170. The bill bars reimbursing a physician below their contracted rate simply because they dispensed the drug, and it outlaws contract terms that penalize or discourage physician dispensing, termination or non‑contracting based on dispensing, and retaliation against physicians asserting rights under the statute.
Compliance with federal and state controlled‑substance rules
This provision clarifies that nothing in the statute overrides federal or state laws governing controlled substances, including DEA registration requirements to dispense controlled drugs. It is a narrow carve‑in that preserves criminal and regulatory obligations for dispensing controlled medications, not a substantive limit on the antisteering rules.
Consent and good‑faith cost estimate duty for providers
When the site or provider that actually supplies or administers an injected or infused medication differs from the site the insurer or PBM directed, the delivering provider, physician’s office, clinic, infusion center, or pharmacy must obtain the insured’s consent and give a good‑faith estimate of the insured’s cost‑sharing amount before providing the drug. This creates a pre‑treatment communication obligation that will affect clinic intake, consent forms, and billing procedures.
Definitions and exclusions (PBM, medically necessary, facility exclusion)
The definitions section repeats a broad, operational definition of pharmacy benefit manager and cross‑references the statutory meaning of “medically necessary.” It also expressly excludes outpatient departments of general acute care hospitals from the definition of physician’s office, clinic, or infusion center, which steers the statute’s protections toward freestanding and clinic settings and away from hospital outpatient care.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients receiving complex infused or injected therapies (e.g., oncology, biologics for autoimmune disease): the bill preserves clinician judgment about site‑of‑care and prevents plans from mandating self‑administration or inconvenient mail‑order channels that could compromise safety or adherence.
- In‑network physician offices and independent infusion centers: the law protects their ability to administer covered drugs without being bypassed by plan‑directed mail‑order or preferred external infusion networks and reduces the risk of payment denials for in‑office administration.
- Prescribers who dispense under Business & Professions Code Section 4170 and community pharmacies: the bill defends prescriber and pharmacy dispensing practices against contractual clauses designed to discourage or penalize dispensing.
- Patient financial counselors and clinic billing staff: the requirement to provide a good‑faith estimate before treatment gives these teams clearer billing expectations and a tool to counsel patients on out‑of‑pocket exposure.
Who Bears the Cost
- Health insurers and pharmacy benefit managers operating in California: they lose certain site‑of‑care steering levers and may face higher costs if plans must reimburse more frequently for office/clinic administration and cannot mandate lower‑cost mail‑order channels.
- Mail‑order and preferred pharmacy networks: these entities may see reduced volume for infused drug supply and oral medication dispensing when prescribers or clinics dispense or use alternative in‑network pharmacies.
- Plan contracting and provider network teams: insurers and PBMs will need to revise contracts, develop compliance protocols, and possibly renegotiate rates to ensure they do not include prohibited steering or discriminatory clauses.
- Small physician practices and clinics: while protected from discriminatory contract terms, these providers must absorb administrative work to produce good‑faith cost estimates and obtain consent, which could increase staff burden.
Key Issues
The Core Tension
The bill pits patient‑centered, clinician‑led site‑of‑care decisions against payers’ ability to direct dispensing and site choices as a cost‑control tool; enforcing clinician judgment increases access and safety for some patients but reduces payers’ leverage to steer volume to lower‑cost channels, potentially raising premiums or shifting costs elsewhere. There is no mechanism in the statute to reconcile that trade‑off beyond forcing the negotiation to occur at network contracting and regulatory interpretation stages.
AB 577 raises immediate implementation questions that the statutory text does not resolve. First, the bill contains no explicit enforcement mechanism, civil penalty, or private right of action; it is unclear whether regulators would rely on existing Department of Insurance authority, seek administrative enforcement, or whether patients would be able to sue for violations.
That gap matters: absent clear remedies, plans and PBMs may have weak incentives to change entrenched steering practices.
Second, the statute sits beside a thicket of federal law — most importantly ERISA preemption for self‑insured employer plans. The bill does not address preemption, so its practical reach may be limited to fully insured California plans.
That creates a two‑tier market where the protections apply only to some enrollees, complicating provider operations, payer contracting, and patient expectations. Drafting duplications and ambiguous phrasing (two overlapping PBM definitions, syntactic glitches around “medically necessary,” and an unclear standard for what counts as a “lesser than the contracted rate”) further raise interpretive questions that regulators or courts will have to resolve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.